Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical

Drug Profile

Omalizumab biosimilar - Shanghai Zhangjiang Biotechnology/Shanghai Biomabs Pharmaceutical

Alternative Names: Aomaishu; CMAB-007

Latest Information Update: 29 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Biomabs Pharmaceuticals; Shanghai Zhangjiang Biotechnology
  • Developer Shanghai Biomabs Pharmaceuticals
  • Class Antiallergics; Antiasthmatics; Monoclonal antibodies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic asthma

Most Recent Events

  • 13 Aug 2018 Omalizumab biosimilar licensed to Sinomab
  • 13 Aug 2018 Omalizumab biosimilar sub-licensed by Sinomab to Mabpharm in China and rest of the world excluding Japan, North America and Europe
  • 20 Mar 2018 Phase-III clinical trials in Allergic asthma (In adolescents, In adults, In the elderly) in China (SC) (NCT03468790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top